Clincosm LogoSign in Get a demo

Solid Tumor

Showing NaN - NaN of 53
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor Trial in Beijing (KN035)

Recruiting
  • Solid Tumor
  • KN035
  • Beijing, Beijing, China
    Peking University Cancer Hospital, Peking University
Apr 5, 2022

Solid Tumor, Melanoma Trial in Beijing (OH2 injection, Keytruda)

Recruiting
  • Solid Tumor
  • Melanoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Apr 1, 2022

Solid Tumor, Lymphoma Trial in Beijing (HG146, PD-(L)1 antibody)

Recruiting
  • Solid Tumor
  • Lymphoma
  • Beijing, China
    National Cancer Center/Cancer Hospital
Mar 16, 2022

Solid Tumor Trial in Beijing (HMPL-453, gemcitabine and cisplatin, toripalimab)

Recruiting
  • Solid Tumor
  • Beijing, China
    Chinese PLA General Hospital
Mar 4, 2022

Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma Trial in China (AB011 Injection)

Recruiting
  • Solid Tumor
  • +2 more
  • AB011 Injection
  • Hefei, Anhui, China
  • +11 more
Feb 7, 2022

Solid Tumor Trial in Beijing (KD6001 Injection)

Recruiting
  • Solid Tumor
  • KD6001 Injection
  • Beijing, China
    Beijing Cancer Hospital
Jan 28, 2022

Solid Tumor Trial in China (SHR-1701, Famitinib)

Recruiting
  • Solid Tumor
  • Hefei, Anhui, China
  • +15 more
Jan 11, 2022

Solid Tumor Trial in Beijing, Zhengzhou, Hangzhou (HL-085, Vemurafenib)

Recruiting
  • Solid Tumor
  • Beijing, Beijing, China
  • +3 more
Jan 20, 2022

Solid Tumor, NSCLC, Head Neck Cancer Trial in China (MCLA-129)

Recruiting
  • Solid Tumor
  • +3 more
  • Baoding, China
  • +63 more
Dec 19, 2021

Solid Tumor Trial in Beijing (TQB3811)

Recruiting
  • Solid Tumor
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Dec 2, 2021

Solid Tumor Trial in Beijing (JK-1201I)

Completed
  • Solid Tumor
  • Beijing, Beijing, China
    The fifth medical center of PLA general hospital
Nov 16, 2021

Solid Tumor Trial in Beijing (Sacituzumab Govitecan-hziy)

Recruiting
  • Solid Tumor
  • Sacituzumab Govitecan-hziy
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 3, 2021

Solid Tumor Trial in Beijing, Harbin (lenvatinib)

Completed
  • Solid Tumor
  • Beijing, Beijing, China
  • +1 more
Sep 27, 2021

Solid Tumor Trial in Beijing, Shanghai (utidelone injection)

Recruiting
  • Solid Tumor
  • utidelone injection
  • Beijing, China
  • +2 more
Aug 27, 2021

NSCLC, CRC, Solid Tumor Trial in Beijing (JAB-21822)

Recruiting
  • NSCLC
  • +2 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 11, 2021

Solid Tumor, Breast Cancer Trial in China (FS-1502)

Recruiting
  • Solid Tumor
  • Breast Cancer
  • Beijing, Beijing, China
  • +4 more
Jul 7, 2021

Solid Tumor Trial in Beijing (AB-106)

Recruiting
  • Solid Tumor
  • Beijing, China
    Chinese PLA General Hospital
Jun 18, 2021

Solid Tumor Trial in China (RC108)

Recruiting
  • Solid Tumor
  • Beijing, Beijing, China
  • +4 more
Jun 10, 2021

Solid Tumor, Lymphoma Trial in Beijing (Manganese Chloride, Radiotherapy, Chemo-immunotherapy)

Recruiting
  • Solid Tumor
  • Lymphoma
  • Manganese Chloride
  • +2 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
May 4, 2021

Solid Tumor Trial in Beijing (Apatinib and Camrelizumab for Injection)

Recruiting
  • Solid Tumor
  • Apatinib and Camrelizumab for Injection
  • Beijing, Beijing, China
  • +1 more
Apr 2, 2021

Solid Tumor Trial in Beijing (SHR2150, Anti-Cancer Agent)

Unknown status
  • Solid Tumor
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Oct 15, 2020

Solid Tumor, Lymphoma, Malignant Trial in Beijing, Changsha, Guang Zhou (Enzastaurin)

Completed
Has Results
  • Solid Tumor
  • Lymphoma, Malignant
  • Beijing, China
  • +2 more
Sep 14, 2020

Solid Tumor, Lymphoma Trial in Beijing (SHR2554+SHR1701, SHR1701)

Recruiting
  • Solid Tumor
  • Lymphoma
  • Beijing, China
    Department of Biotherapeutic, Chinese PLA General Hospital
Sep 22, 2020

Solid Tumor Trial in Beijing (Surufatinib/humanized anti-PD-1 mAb)

Unknown status
  • Solid Tumor
  • Surufatinib/humanized anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 27, 2019

Capecitabine-based Chemotherapy Toxicities in Chinese Solid

Unknown status
  • Solid Tumor
  • +4 more
  • detection of genotype
  • Beijing, Beijing, China
  • +6 more
Aug 27, 2019